Thc Therapeutics Stock Net Income
| THCT Stock | USD 0.0001 0.02 99.47% |
As of the 9th of February, THC Therapeutics owns the risk adjusted performance of 0.1175, and Standard Deviation of 573.6. Compared to fundamental indicators, the technical analysis model makes it possible for you to check helpful technical drivers of THC Therapeutics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from THC Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting THC Therapeutics' valuation are summarized below:THC Therapeutics does not today have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. THC |
THC Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to THC Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of THC Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in THC Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding THC Therapeutics or generate 0.0% return on investment in THC Therapeutics over 90 days. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested... More
THC Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure THC Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess THC Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1333 | |||
| Maximum Drawdown | 4749.47 | |||
| Value At Risk | (50.00) | |||
| Potential Upside | 100.0 |
THC Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for THC Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as THC Therapeutics' standard deviation. In reality, there are many statistical measures that can use THC Therapeutics historical prices to predict the future THC Therapeutics' volatility.| Risk Adjusted Performance | 0.1175 | |||
| Jensen Alpha | 79.77 | |||
| Total Risk Alpha | 19.8 | |||
| Treynor Ratio | (1.87) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of THC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
THC Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1175 | |||
| Market Risk Adjusted Performance | (1.86) | |||
| Mean Deviation | 148.21 | |||
| Coefficient Of Variation | 749.57 | |||
| Standard Deviation | 573.6 | |||
| Variance | 329014.05 | |||
| Information Ratio | 0.1333 | |||
| Jensen Alpha | 79.77 | |||
| Total Risk Alpha | 19.8 | |||
| Treynor Ratio | (1.87) | |||
| Maximum Drawdown | 4749.47 | |||
| Value At Risk | (50.00) | |||
| Potential Upside | 100.0 | |||
| Skewness | 8.04 | |||
| Kurtosis | 65.05 |
THC Therapeutics Backtested Returns
THC Therapeutics is out of control given 3 months investment horizon. THC Therapeutics retains Efficiency (Sharpe Ratio) of 0.17, which indicates the firm had a 0.17 % return per unit of volatility over the last 3 months. We were able to break down twenty different technical indicators, which can help you to evaluate if expected returns of 22.23% are justified by taking the suggested risk. Use THC Therapeutics risk adjusted performance of 0.1175, and Standard Deviation of 573.6 to evaluate company specific risk that cannot be diversified away. THC Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The entity owns a Beta (Systematic Risk) of -40.92, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning THC Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, THC Therapeutics is expected to outperform it. Use THC Therapeutics coefficient of variation, total risk alpha, as well as the relationship between the Total Risk Alpha and rate of daily change , to analyze future returns on THC Therapeutics.
Auto-correlation | 0.18 |
Very weak predictability
THC Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between THC Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of THC Therapeutics price movement. The serial correlation of 0.18 indicates that over 18.0% of current THC Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.18 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, THC Therapeutics reported net income of (1.89 Million). This is 100.55% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.33% higher than that of the company.
THC Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses THC Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of THC Therapeutics could also be used in its relative valuation, which is a method of valuing THC Therapeutics by comparing valuation metrics of similar companies.THC Therapeutics is currently under evaluation in net income category among its peers.
THC Fundamentals
| Return On Asset | -5.57 | |||
| Current Valuation | 1.57 M | |||
| Shares Outstanding | 34.15 M | |||
| Shares Owned By Insiders | 30.84 % | |||
| Price To Earning | 1.25 X | |||
| Price To Book | 46.07 X | |||
| EBITDA | (1.06 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 3.82 K | |||
| Total Debt | 925.89 K | |||
| Debt To Equity | 18.70 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.15) X | |||
| Cash Flow From Operations | (388.48 K) | |||
| Earnings Per Share | (0.09) X | |||
| Beta | 1.71 | |||
| Market Capitalization | 1.09 M | |||
| Total Asset | 480.07 K | |||
| Z Score | -6.0 | |||
| Net Asset | 480.07 K |
About THC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze THC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.